SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. announced today that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Conference in New York City. Peter Thompson, M.D., FACP, president, chief executive officer and chairman of the board of directors, and Michelle Burris, senior vice president and chief financial officer, are scheduled to present on Monday, Sept. 14 at 8 a.m. EDT. The presentation will be available via audio webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2400648.
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet Biotech collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.
SOURCE Trubion Pharmaceuticals, Inc.
CONTACT: Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals, Inc., +1-206-838-0500, jdenike@trubion.com; or Amy Petty,
Senior Account Executive of Waggener Edstrom Worldwide Healthcare,
+1-617-576-5788, amyp@waggeneredstrom.com, for Trubion Pharmaceuticals,
Inc.
Web site: http://www.trubion.com/